JP6836905B2 - 尿素サイクル障害及び神経変性障害におけるベンゾエート含有組成物の使用 - Google Patents

尿素サイクル障害及び神経変性障害におけるベンゾエート含有組成物の使用 Download PDF

Info

Publication number
JP6836905B2
JP6836905B2 JP2016565117A JP2016565117A JP6836905B2 JP 6836905 B2 JP6836905 B2 JP 6836905B2 JP 2016565117 A JP2016565117 A JP 2016565117A JP 2016565117 A JP2016565117 A JP 2016565117A JP 6836905 B2 JP6836905 B2 JP 6836905B2
Authority
JP
Japan
Prior art keywords
mice
pharmaceutical composition
gtb
eae
day
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2016565117A
Other languages
English (en)
Japanese (ja)
Other versions
JP2017505811A (ja
JP2017505811A5 (enExample
Inventor
パハン，カリパダ
Original Assignee
ラッシュ・ユニバーシティ・メディカル・センター
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ラッシュ・ユニバーシティ・メディカル・センター filed Critical ラッシュ・ユニバーシティ・メディカル・センター
Publication of JP2017505811A publication Critical patent/JP2017505811A/ja
Publication of JP2017505811A5 publication Critical patent/JP2017505811A5/ja
Application granted granted Critical
Publication of JP6836905B2 publication Critical patent/JP6836905B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/235—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Nutrition Science (AREA)
  • Emergency Medicine (AREA)
  • Food Science & Technology (AREA)
  • Polymers & Plastics (AREA)
  • Mycology (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Physiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Urology & Nephrology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
JP2016565117A 2014-01-17 2015-01-16 尿素サイクル障害及び神経変性障害におけるベンゾエート含有組成物の使用 Active JP6836905B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201461928622P 2014-01-17 2014-01-17
US61/928,622 2014-01-17
PCT/US2015/011798 WO2015109215A1 (en) 2014-01-17 2015-01-16 The use of a benzoate containing composition in urea cycle disorders and neurodegenerativre disordrs

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2019191224A Division JP2020037558A (ja) 2014-01-17 2019-10-18 尿素サイクル障害及び神経変性障害におけるベンゾエート含有組成物の使用

Publications (3)

Publication Number Publication Date
JP2017505811A JP2017505811A (ja) 2017-02-23
JP2017505811A5 JP2017505811A5 (enExample) 2018-02-22
JP6836905B2 true JP6836905B2 (ja) 2021-03-03

Family

ID=53543490

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2016565117A Active JP6836905B2 (ja) 2014-01-17 2015-01-16 尿素サイクル障害及び神経変性障害におけるベンゾエート含有組成物の使用
JP2019191224A Pending JP2020037558A (ja) 2014-01-17 2019-10-18 尿素サイクル障害及び神経変性障害におけるベンゾエート含有組成物の使用

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2019191224A Pending JP2020037558A (ja) 2014-01-17 2019-10-18 尿素サイクル障害及び神経変性障害におけるベンゾエート含有組成物の使用

Country Status (16)

Country Link
US (1) US9968582B2 (enExample)
EP (1) EP3094616B1 (enExample)
JP (2) JP6836905B2 (enExample)
CA (1) CA2936548C (enExample)
CY (1) CY1124115T1 (enExample)
DK (1) DK3094616T3 (enExample)
ES (1) ES2853974T3 (enExample)
HR (1) HRP20210361T1 (enExample)
HU (1) HUE053671T2 (enExample)
LT (1) LT3094616T (enExample)
PL (1) PL3094616T3 (enExample)
PT (1) PT3094616T (enExample)
RS (1) RS61611B1 (enExample)
SI (1) SI3094616T1 (enExample)
SM (1) SMT202100074T1 (enExample)
WO (1) WO2015109215A1 (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2020536098A (ja) * 2017-10-06 2020-12-10 ラッシュ・ユニバーシティ・メディカル・センター グリシン脳症を治療するためのベンゾエート含有組成物の使用
EP3713556A4 (en) * 2017-11-22 2021-10-20 Chieh-Hsin Lin BENZOIC ACID OR A SALT AND DERIVATIVE THEREOF FOR USE IN THE PREVENTION OR TREATMENT OF DEPRESSION
EA202192199A1 (ru) 2019-02-25 2021-12-17 Раш Юниверсити Медикал Сентер Композиции, содержащие коричную кислоту, и способы их применения
JP2022541021A (ja) * 2019-07-16 2022-09-21 ラッシュ・ユニバーシティ・メディカル・センター 神経変性障害を治療するためのベンゾエート含有組成物の使用
CN116390761A (zh) 2020-10-28 2023-07-04 拉什大学医学中心 肉桂酸苄酯组合物在治疗甘氨酸脑病和尿素循环障碍中的应用
WO2022132894A1 (en) * 2020-12-16 2022-06-23 Rush University Medical Center Administration of glycerol tribenzoate and glycerol phenylbutyrate for treatment of neurodegenerative and urea cycle disorders
EP4447952A4 (en) * 2021-12-16 2025-11-19 Us Gov Veterans Affairs Benzoic acid salts for the treatment of injuries and disorders of the nervous system

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4284647A (en) * 1980-03-31 1981-08-18 The Johns Hopkins University Process for waste nitrogen removal
US20080171792A1 (en) * 2006-12-28 2008-07-17 Jobdevairakkam Christopher New Use of highly concentrated formulations of 4-phenylbutyrate for treatment of certain disorders

Also Published As

Publication number Publication date
RS61611B1 (sr) 2021-04-29
SI3094616T1 (sl) 2021-07-30
HRP20210361T1 (hr) 2021-04-16
LT3094616T (lt) 2021-04-12
SMT202100074T1 (it) 2021-05-07
JP2017505811A (ja) 2017-02-23
DK3094616T3 (da) 2021-02-15
HUE053671T2 (hu) 2021-07-28
PT3094616T (pt) 2021-03-03
ES2853974T3 (es) 2021-09-20
EP3094616A4 (en) 2017-08-23
CA2936548A1 (en) 2015-07-23
WO2015109215A1 (en) 2015-07-23
EP3094616B1 (en) 2020-12-23
CY1124115T1 (el) 2022-05-27
CA2936548C (en) 2022-08-30
JP2020037558A (ja) 2020-03-12
EP3094616A1 (en) 2016-11-23
PL3094616T3 (pl) 2021-05-31
US20160331714A1 (en) 2016-11-17
US9968582B2 (en) 2018-05-15

Similar Documents

Publication Publication Date Title
JP2020037558A (ja) 尿素サイクル障害及び神経変性障害におけるベンゾエート含有組成物の使用
JP6250588B2 (ja) Ｌ−オルニチンフェニル酢酸塩を用いる門脈圧亢進の治療及び肝機能の修復
CN102548571A (zh) 用于预防和治疗脑部疾病和疾病状态的组合物和方法
US12478598B2 (en) Compositions including cinnamic acid and methods of use thereof
AU2022200277A1 (en) The use of a benzoate containing composition to treat glycine encephalopathy
KR20140091645A (ko) 간 손상 위험의 관리에 사용하기 위한 약물의 제조를 위한 드로네다론의 용도
US20230255910A1 (en) Use of a cinnamein composition for the treatment of glycine encephalopathy and urea cycle disorders
CN109806250A (zh) 一种含羟基脲的药物组合物的应用
WO2025175626A1 (zh) 一种预防或治疗阿尔兹海默症的益生菌剂及其应用
Gaudet et al. Safety and efficacy of evinacumab, a monoclonal antibody to ANGPTL3, in patients with homozygous familial hypercholesterolemia: A single-arm, open-label, proof-of-concept study
TW201944995A (zh) 治療嚴重便祕的組合物及方法
US8206760B2 (en) Composition for inhibition of transplant rejection containing the cordyceps mycellia extract as an active ingredient
HUE029189T2 (en) The use of aminosalicylates in diarrhea prodominant irritable bowel syndrome
CN115429799A (zh) Magl抑制剂在制备预防或治疗肝炎药物中的用途
CA2544136C (fr) Utilisation de l'agomelatine pour l'obtention de medicaments destines au traitement des troubles bipolaires
CN112516160A (zh) 一种医药组合物及其医药用途
CN114984034A (zh) 一种寡糖类化合物的应用
KR20240049578A (ko) 트리카프릴린을 이용한 편두통 및 관련 두통 증상 치료 방법
CN113194940A (zh) 治疗脂肪肝的包含单乙酰基二酰基甘油化合物的组合物
WO2017146305A1 (ko) 급성관동맥증후군에 동반되는 우울증 치료용 약제학적 조성물
CN110840902A (zh) 鞣酸在制备抑制瘙痒的药物中的用途

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20160927

A711 Notification of change in applicant

Free format text: JAPANESE INTERMEDIATE CODE: A711

Effective date: 20160927

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20180112

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20180112

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20180926

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20181002

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20181221

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20190301

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20190618

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20191018

C60 Trial request (containing other claim documents, opposition documents)

Free format text: JAPANESE INTERMEDIATE CODE: C60

Effective date: 20191018

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20191029

C21 Notice of transfer of a case for reconsideration by examiners before appeal proceedings

Free format text: JAPANESE INTERMEDIATE CODE: C21

Effective date: 20191105

A912 Re-examination (zenchi) completed and case transferred to appeal board

Free format text: JAPANESE INTERMEDIATE CODE: A912

Effective date: 20191227

C211 Notice of termination of reconsideration by examiners before appeal proceedings

Free format text: JAPANESE INTERMEDIATE CODE: C211

Effective date: 20200107

C22 Notice of designation (change) of administrative judge

Free format text: JAPANESE INTERMEDIATE CODE: C22

Effective date: 20200707

C13 Notice of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: C13

Effective date: 20200915

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20201020

C22 Notice of designation (change) of administrative judge

Free format text: JAPANESE INTERMEDIATE CODE: C22

Effective date: 20201124

C23 Notice of termination of proceedings

Free format text: JAPANESE INTERMEDIATE CODE: C23

Effective date: 20201216

C03 Trial/appeal decision taken

Free format text: JAPANESE INTERMEDIATE CODE: C03

Effective date: 20210126

C30A Notification sent

Free format text: JAPANESE INTERMEDIATE CODE: C3012

Effective date: 20210126

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20210208

R150 Certificate of patent or registration of utility model

Ref document number: 6836905

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250